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What is known 
• Community acquired pneumonia in children is diagnosed based on clinical and 
radiological definitions 
• Radiological criteria were standardized by WHO-SICR and have been utilized in 
vaccine studies 
 
What is New:  
• Correlation between the WHO-SICR radiological definitions and clinical and 
laboratory parameters has not been studied 
• Using the WHO-SICR radiological definitions for community acquired alveolar 
pneumonia (CAAP) and non-CAAP and the study definition for clinical CAP, it 
was found that the groups are distinct, differing clinically and in laboratory 
parameters 
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ABSTRACT  
Chest radiographs from children with community acquired pneumonia (CAP) were categorized into three 
distinct presentations and each presentation was correlated to clinical and laboratory findings. Children <59 
months with CAP presenting to pediatric emergency rooms during two years were enrolled prospectively in 
eight centers across Europe. Clinical and laboratory data were documented and radiographs obtained from 
patients. Of the 1,107 enrolled patients, radiographs were characterized as 74.9% alveolar CAP, 8.9% non-
alveolar CAP and 16.3% clinical CAP. Alveolar CAP patients had significantly higher rates of fever 
(90.7%), vomiting (27.6%), and abdominal pain (18.6%), while non-alveolar CAP patients presented more 
with cough (96.9%). A model using independent parameters that characterize alveolar, non-alveolar and 
clinical CAP demonstrated that alveolar CAP patients were significantly older (OR= 1.02) and had 
significantly lower oxygen saturation than non-alveolar CAP patients (OR= 0.54). Alveolar CAP patients 
had significantly higher mean WBC (17,760±8539.68 cells/mm3) and ANC (11.5±7.5 cells/mm3) than 
patients categorized as non-alveolar CAP (WBC: 15,160±5996 cells/mm3, ANC: 9.2±5.1 cells/mm3) and 
clinical CAP (WBC: 13,180±5892, ANC: 7.3±4.7). Conclusion: Alveolar CAP, non-alveolar CAP and 
clinical CAP are distinct entities differing not only by chest radiographic appearance but also in clinical 
and laboratory characteristics. Alveolar CAP has unique characteristics, which suggest association with 
bacterial etiology.  
 
List of abbreviations 
ANC Absolute neutrophil count 
CAP Community Acquired Pneumonia 
CAP-RI Community Acquired Pneumonia Pediatric Research Initiative 
CRP C-reactive protein 
ESR Erythrocyte sedimentation rate 
PCV Packed Cell Volume 
WHO World Health Organization 
WHO-SICR World Health Organization working group - WHO Standardization of Interpretation of Chest 
Radiographs 
WBC White Blood cells 
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INTRODUCTION 
Community-acquired pneumonia (CAP) is the leading cause of childhood morbidity and mortality in 
industrialized as well as in developing countries, and is responsible for approximately 1.4 million deaths 
per year which represents 18.3% of all deaths in children <5yrs [11]. CAP has an average annual incidence 
of 33.8 cases/10,000 in children under the age of 5 [3]. A large number of microorganisms can cause 
childhood pneumonia both bacterial and viral and sometimes it is caused by multiple pathogens at once as a 
co-infection [7]. Management of CAP in children involves a number of therapeutic decisions including 
antibiotic treatment that depends on the infective agent [1]. Treatment for pneumonia is often empirically 
based on the likelihood that the pneumonia is bacterial in origin, since lung aspirates are too invasive and 
blood culture unreliable.  
The diagnosis of pneumonia is based primarily on an algorithm built on the patient’s history, 
clinical signs and symptoms, laboratory tests and chest radiograph findings. Case definitions for pneumonia 
can vary by geographic region and even between various hospitals as a result of different institutions using 
different guidelines [1,6,21]. Laboratory tests measuring the systemic inflammatory response associated 
with pneumonia are used routinely in clinical practice but their sensitivity and specificity are relatively low 
[18,19]. 
Despite using radiological findings as a “gold standard” for defining pneumonia, there is 
considerable variability in diagnosis of radiographic type of CAP due to inconsistent interpretations of chest 
radiographs among physicians [16]. Thus, the World Health Organization (WHO) working group - “WHO 
Standardization of Interpretation of Chest Radiographs” (WHO-SICR) developed a standardized 
radiological diagnosis of CAP attempting to characterize it [2]. These definitions include three entities: 1) 
alveolar pneumonia: alveolar infiltrate and consolidation, pleural effusion 2) non-alveolar pneumonia: other 
infiltrates, no consolidation infiltrate, without effusion 3) no infiltrate, consolidations or effusions [2]. 
Because alveolar pneumonia is considered to more frequently have a bacterial etiology [20], characterizing 
CAP by radiographic presentation can help predict which types of pneumonia will be reduced by anti-
bacterial vaccines such as pneumococcal conjugated vaccines (PCV). These definitions were used to 
evaluate various PCV in the past. The demonstrated efficacy of the vaccines was between 17.7% and 37.0% 
[4,10].  
Although these radiological definitions of pneumonia are becoming more commonly used, 
differences in clinical symptoms and laboratory results among the three entities are not well studied. 
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Because of the established association of alveolar pneumonia with bacterial etiology, we hypothesized in 
this study that patients with alveolar CAP would exhibit clinical and laboratory features typical of bacterial 
infections and that the other two presentations (non-alveolar and clinical CAP) would exhibit clinical and 
laboratory features associated with viral infection. The aim of this study was to compare clinical symptoms 
and laboratory results between patients with radiographic presentations of alveolar, non-alveolar, and 
clinical CAP, in order to help physicians to determine appropriate treatment for pediatric pneumonia.  
 
PATIENTS AND METHODS 
Setting  
This was a prospective observational study, which took place from November 1, 2010 until June 30, 2012. 
Data was collected as part of the Community Acquired Pneumonia Pediatric Research Initiative (CAP-
PRI), a consortium established by different countries across Europe. Participating medical centers are 
located in eight countries: Greece, Israel, Italy, Lithuania, Portugal, Romania, Spain and UK. In each 
country one major pediatric hospital or service is included in the consortium, except in Greece where two 
hospitals participated. Each participating center of CAP-PRI received approval for this study from their 
local Human Ethics Committee. 
 
Enrollment Criteria   
All children attending the emergency departments of the CAP-PRI centers presenting with CAP who were 
less than 59 months of age, that had a chest radiograph obtained within 24 hours of admission to the 
hospital were included in the study. All pneumonia episodes were at least one month following the 
diagnosis of a previous pneumonia episode. 
 
Survey 
The following areas were covered by an audit questionnaire collected at enrollment: demographic data (age 
and gender), medical history including vaccinations, physical findings, and current health status. 
Information was obtained from medical charts and any missing information was completed by interviewing 
parents, the pediatricians on duty at the hospital or the primary care physicians for outpatients. Clinical 
parameters assessed and recorded included: temperature (maximal temperature that was measured during 
illness), blood O2 saturation, respiratory rate, if hospitalized and duration of hospitalization, presence of 
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cough, vomiting, abdominal pain (as reported by parents), rhinorrhea, and vaccination status. The 
following laboratory tests were documented: white blood cells count (WBC), C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR) and absolute neutrophil count (ANC). A patient was considered fully 
vaccinated according to the local vaccination recommendations of each country. All medical centers 
followed the same protocol that was written by members of the CAP-PRI consortium. 
 
Chest Radiograph x-rays Evaluation 
All radiographs were evaluated according to WHO-SICR criteria [2] by a single expert pediatrician who 
was blinded to the clinical and laboratory data of the patients. Radiographs were from prospectively 
enrolled children, and were categorized into radiographic categories retrospectively. The WHO-SICR 
classifications used in the study were as follows: 
• Alveolar CAP-	The presence of end-point consolidation (a dense or fluffy opacity that 
occupies a portion or whole of a lobe or of the entire lung, that may or may not contain 
air-bronchograms) or pleural effusion that is in the lateral pleural space (and not just in 
the minor or oblique fissure) and was spatially associated with a pulmonary 
parenchymal infiltrate (including other infiltrate) OR if the effusion obliterated enough 
of the hemithorax to obscure an opacity. 
• Non-alveolar CAP- The presence of other (non-end-point) infiltrate as defined above in the 
absence of a pleural effusion. 
• Clinical CAP- absence of end-point consolidation, other infiltrate or pleural effusion 
 
Statistical analysis 
Demographic, clinical and laboratory characteristics were described by radiographic type of pneumonia for 
different age groups: 0-23, 24-59 months and in general. Frequencies and proportions (means and standard 
deviations) were reported for categorical variables (continuous variables). Chi-square, Fisher, ANOVA, 
One way-test or Kruskal-Wallis tests were implemented to assess the association between the type of 
pneumonia and characteristics. When ANOVA (One way-test) was significant, the multiple comparisons 
Tukey test (Dunnett’s Modified Tukey-Kramer) was implemented and if Chi-square was significant a 
pairwise proportion test was developed.  
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To compare the different types of pneumonia, a multinomial mixed Bayesian model with missing 
values adjusted by age, O2 saturation, hospital (random effect), ANC and vaccine status was developed. 
Vaccine status and ANC with missing values were imputed in the model taking into account the absence of 
randomness. Inside the model a logistic regression adjusted by hospital was implemented for imputed 
vaccine status variable. ANC had no random missing values, the probability of missing values is related to 
hospitalization and age, and this probability intervened in the imputation process. 
 
RESULTS 
A total of 1,107 patients were enrolled. Alveolar CAP was diagnosed in 829 (74.9%), non-alveolar CAP in 
98 (8.9%), and clinical CAP in 180 (16.3%) patients (Figure 1).  
Children with alveolar CAP were significantly older than those with non-alveolar CAP (Table 1 
and 4).  Patients with alveolar CAP, had higher rates of fever than those with non-alveolar CAP (90.7% 
and 87.8% respectively, p<0.05) and in addition a higher percentage of patients with alveolar CAP had 
CRP >70µg/L than non-alveolar CAP (37.8% and 16.6% respectively, p<0.05) (Figure 2). Vomiting and 
abdominal pain were also more common in alveolar CAP patients when compared to non-alveolar and 
clinical CAP patients (p<0.05) (Figure 2). Rhinorrhea was found at equal rates in alveolar and non-alveolar 
CAP patients (~64%) but significantly less in clinical CAP patients (41%, p<0.001 both) (Figure 2). Cough 
was significantly different amongst all groups and had highest rates in non-alveolar CAP (97%) followed 
by alveolar CAP (89.5%) and clinical CAP (81.1%) patients (Figure 1). No significant differences in 
gender, mean temperature, and respiratory rate (when not separated by age) were found between the 
radiographic groups. Inflammatory markers including WBC, ANC and ESR were highest in the alveolar 
CAP patient group followed by non-alveolar CAP patient group and lowest in the clinical CAP group 
(Table 1). Mean CRP was highest in the alveolar CAP group, followed by clinical CAP and lowest in non-
alveolar CAP (Table 1). Number of days of fever, were also significantly higher for patients with alveolar 
CAP than non-alveolar and clinical CAP. Vaccination status was not significantly different among groups. 
(Tables 2 and 3). 
When divided into two age groups: 0-23 months and 24-59 months different variables were 
significant in each group. Rate of fever >38.5°C was significant for patients 23-59 months old but not for 
patients 0-23 months old. Cough was insignificant in the older age group. When respiratory rate was 
adjusted for age (0-23 months with a cut-off of ≥50 breaths/minute [bpm] and 23-59 months ≥	40bpm), 
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respiratory rate was significantly different between radiographic groups. Respiratory rate was significantly 
higher in those with alveolar CAP than non-alveolar CAP and clinical CAP in the younger group, while in 
the older group the trend was significantly the opposite and those with alveolar CAP had lower respiratory 
rate. In the younger age group neither abdominal pain nor hospitalization was significantly different among 
groups; however in the older group both of these parameters were significantly higher in alveolar CAP 
patients than clinical CAP patients.  CRP >70µg/L was significantly different in patients diagnosed as non- 
alveolar CAP and clinical CAP in the younger group, and was significantly higher in alveolar CAP patients 
than non-alveolar and clinical CAP patients in the older group. Mean CRP was only significant in the older 
group (Tables 2 and 3).  
In a multi-regression analysis model, patients with alveolar CAP compared to other entities had higher 
ANC and were older. For each year of age the probability of alveolar pneumonia increases by 2% (OR: 
1.02, 95% CI: 1.01-1.04). Fully vaccinated patients were less likely to have alveolar CAP than non-alveolar 
and clinical CAP. If oxygen saturation was ≤94% the probability of having alveolar CAP was nearly 50% 
higher when compared to non-alveolar CAP (OR: 0.54, 95% CI: 0.33-0.04). When <92% O2 saturation was 
used in the model it was not found to be an independent risk of non-alveolar CAP (Table 4). 
 
DISCUSSION 
The three radiologically-defined categories alveolar, non-alveolar and clinical CAP differ in demographic, 
clinical and laboratory characteristics. Alveolar CAP was seen in older children, with higher WBC, ANC, 
ESR, CRP and more vomiting and abdominal pain. Children with non-alveolar CAP had more cough (in 
younger children), rhinorrhea (in older children) and a slightly lower rate of fever (in younger children) 
than alveolar and clinical CAP. Clinical CAP presented more similarly to alveolar CAP for clinical 
parameters and more similarly to non-alveolar CAP in laboratory parameters. From these findings it seems 
like alveolar CAP has clinical and laboratory characteristics that may indicate bacterial etiology whereas 
non-alveolar CAP has the clinical and laboratory characteristics that may indicate viral etiology. The 
characteristics of clinical CAP do not seem to hint toward a specific etiology. 
 Age is an important parameter that was a significant predictor of risk of alveolar versus non-
alveolar CAP. In the present study, alveolar CAP was seen in older patients. It has been shown in previous 
studies that cases of alveolar pneumonia are usually of more bacterial etiology [2,13,20] that becomes more 
common with increasing age [7,14]. In the present study we observed a correlation between alveolar CAP 
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and older age and we can speculate that this is due to the fact that alveolar CAP is more frequently 
associated with bacterial etiology. In the present study, non-alveolar CAP was more common in younger 
children. Incidence of viral etiology is higher in those <2 years old [7]. Potentially, in this study, non-
alveolar CAP is associated with younger age because it is more often due to viral etiology.  
Clinical results from the study show that alveolar CAP is more consistent with bacterial 
symptoms, while non-alveolar CAP is more consistent with viral symptoms. Abdominal pain was more 
prevalent in cases of alveolar CAP than in other entities. More abdominal pain was reported in a previous 
study in patients with pneumococcal pneumonia (one of the most common pathogens for bacterial 
pneumonia) when compared to patients with RSV pneumonia (the most common etiology of viral 
pneumonia) [8]. It is thought that abdominal pain in bacterial infection may be caused by mesenteric 
lymphadenopathies that are present in lobar or segmental pneumonia [12]. In the present study, non-
alveolar CAP had more frequent viral signs and symptoms such as rhinorrhea, cough, and high respiratory 
rate. These clinical presentations are consistent with viral pneumonia [15]. 
The laboratory results in this study also support the assumption that alveolar CAP cases were more 
associated with bacterial etiology. Alveolar CAP patients had the highest mean WBC, ANC, ESR and CRP 
values, while non-alveolar CAP had lower WBC and CRP. Bacterial etiologies of pneumonia 
characteristically show more inflammatory features (such as higher WBC, ANC, ESR and CRP) when 
compared to viral etiologies [15]. It was also found in a previous study that RSV pneumonia specifically is 
associated with low WBC as well as low serum CRP when compared to bacterial pneumonia [8]. 
Lower O2 saturation and high respiratory rate were observed in patients 0-23 months old with 
alveolar CAP, while these findings were not observed in the older age group.  Higher respiratory rate and 
lower oxygen saturation is usually indicative of a viral infection, since these infections tend to be more 
diffuse and affect both lungs [9,15]. It was shown that pneumonia caused by bacterial-viral co-infection is 
more common in younger children [7]. We can speculate that in this study, even though alveolar CAP 
seems to be in most cases due to bacterial etiology, patients aged 0-23 months more commonly have viral-
bacterial co-infection and thus exhibit clinical parameters that are consider more as “viral” symptoms 
compared to older children. 
Another observation from this study was that clinical CAP seemed to be most similar to alveolar 
CAP in clinical symptoms, but more similar to non-alveolar CAP in laboratory parameters. This might be 
because clinical pneumonia is in fact an early stage of alveolar CAP or non-alveolar CAP, when it is too 
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early in the progression of the disease to be able to detect infiltration or effusion on a radiograph. Timing of 
laboratory tests in the progression of pneumonia can greatly influence the diagnostic results as was 
previously shown [19]. In an animal study by Stark et al. (2006) it was shown that when mice were co-
infected with RSV and pneumococcus, it took several days for an immune response to develop [17]. Thus, 
it is possible that in patients diagnosed with clinical CAP, diagnostic tests were taken too early before an 
immune response against the pathogen was mounted and thus a pattern in laboratory results could be not be 
recognized. Future studies addressing the correlation between these radiographic entities and timing of the 
presentation of the disease might answer this hypothesis. 
In the present study there were some limitations. One was that each center contributed different 
amounts of cases from each radiographic characterization, resulting in unequal distribution of cases for 
each radiographic entity. However, despite this unequal distribution, consistent results were observed 
across centers (data not presented). An additional limitation was that each country (and thus participating 
center) has different local guidelines regarding vaccination practices, which might create a potential bias. 
Although effects of vaccination was beyond the scope of this study, further studies should look only at one 
specific country to observe local effects of the vaccines (specifically PCV) on a specific entity such as 
alveolar pneumonia. It was demonstrated that alveolar pneumonia cases declined significantly after the 
introduction of PCV-13 which also supports the hypothesis that alveolar CAP has a bacterial etiology and 
may be due to S. pneumoniae [5].  
The absence of information on etiology is another important issue. Since in most cases of CAP 
blood culture is negative and only in few places viral etiology is being done routinely, this data is more 
difficult to acquire. Although in the present study this etiological information was not attainable, it is clear 
that there are major clinical and laboratory differences between radiological groups. In the future, studies 
using more sophisticated methods are recommended to try and establish a tighter association between 
etiology and radiographic findings. 
In the present study it was found that alveolar CAP, non-alveolar CAP and clinical CAP are 
distinct entities differing not only by chest radiographic appearance but also in clinical and laboratory 
characteristics. A patient with alveolar CAP has unique characteristics, which suggest association with 
bacterial etiology such as older age, normal O2 saturation and higher inflammatory responses such as 
elevated WBC and ANC. These clinical and laboratory parameters in conjunction with the chest radiograph 
findings can help clinicians to determine their treatment accordingly. 
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TABLE 1: Demographic, Clinical and Laboratory Characteristics of Pediatric Patients <5 Years with 
Radiographically Distinct Presentations of Community Acquired Pneumonia (CAP) 
 
 Alveolar 
CAP 
Non-Alveolar 
CAP 
Clinical  
CAP 
P 
N 829 (74.9%) 98 (8.9%) 180 (16.3%)  
Age in months  
mean ±SD 24.7±16.8 20.4±14.8 23.4 ± 15.5 0.038α 
Male % (n) 55.9(463) 53.1(52) 52.2(94) NS 
Hospitalization % (n) 84.6(701) 80.6(79) 78.3(141) 0.054β 
Mean temperature  
(℃) ±SD (n) 
38.9±1.1(633) 38.8±0.9(81) 38.6 ± 1.0(94) 0.006β 
Respiratory rate ±SD (n) 44.6±13.9 (712) 44.3±10.9(91) 44.6±11.9(11
0) 
NS 
O2 saturation % (n) 94.8±3.7(823) 94.6±4.1(97) 95.7±3.3(178) 0.0021β, γ 
WBC     
N 744 82 138  
Mean (cells/mm3) ± SD 17760±8540.6 
 
15160±5997 13180±5892 <0.001α, β, γ 
% ≥15000 (n) 57.7 (429) 47.6 (39) 
 
30.4 (42) <0.001β,γ 
% ≥20000 (n) 36.2 (269) 22 (18) 
 
10.1 (14) <0.001α, β, γ 
ANC (cells/mm3) ±SD (n) 11.5±7.5(684) 9.2±5.1(134) 7.3±4.7(80) <0.001α, β, γ 
CRP     
Mean* (µg/L) ±SD (n) 83.9±103.6(254) 43.0±76.6(54) 55.4±69.5(14) 0.008 α 
% ≥70 (n) 97 (38.2%) 9 (16.7 %) 4 (28.6%) 0.006 α 
Mean ESR (mm/hour) ±SD (n) 46.2±31.0(107) 45.4±34.9(13) 34.3±29.4(3) NS 
α- alveolar vs. non-alveolar CAP 
β- alveolar vs. clinical CAP 
γ- non-alveolar vs. clinical CAP 
NS- not significant 
*After log transformation. 
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TABLE 2: Clinical and Laboratory Characteristics of Pediatric Patients 0-23 Months Old with CAP in 
Relation to Radiographic Categorizations 
 
 Alveolar 
CAP 
Non-Alveolar 
CAP 
Clinical  
CAP 
P 
Fever >38.5°C% (n/N) 87.8 (380/433) 78.3 (47/60) 86.8 (79/91) NS 
Rhinorrea% (n/N) 70.0 (303/433) 65.0 (39/60) 44.0 (40/91) <0.001β, 0.018γ 
Cough % (n/N) 90.1 (390/433) 96.7 (58/60) 76.9 (70/91) <0.001β, 0.002γ 
<92 O2 sat % (n/N) 20.9 (90/431) 16.9 (10/60) 13.2 (12/91)  NS 
Respiratory Rate ≥ 50 
breaths/min% (n/N) 48.3 (184/381) 33.3 (18/54) 35.6 (21/59) 0.055α, 0.093β 
Abdominal Pain% (n/N) 3.5 (15/427) 5.0 (3/60) 2.2 (2/91) NS 
Vomiting% (n/N) 24.9 (108/433) 10.0 (6/60) 15.4 (14/91) 0.016α, 0.068β 
Vaccination Complete % (n/N) 67.1 (235/350) 59.2 (29/49) 55.6 (15/27) NS 
Hospitalization% (n/N) 87.8 (380/433) 85 (51/60) 84.6 (77/91) NS 
CRP >70% (n/N) 27.1 (29/107) 11.8 (4/34) 60.0 (3/5) 0.032γ 
Respiratory Rate     
mean(breaths/min)±SD 49.8±13.8 46.6±10.7 47.2±11.7 NS 
Median (breaths/min) 48 47 44  
min-max 18-94 28-72 24-72  
n 381 54 59  
Days of fever      
mean ± SD 3.6±3.7 2.7±2.2 2.7±1.9 <0.001α,ß 
median 2 1 2  
min-max 0-30 0-10 0-9  
n 371 46 76  
WBC      
mean (cells/μl)± SD 17480±8347.4 15750±6372.4 13390±5550.5 <0.001ß 
median 16690 14790 12720  
min-max 2000-56100 4790-32700 1820-33020  
n 393 53 78  
ANC      
mean (cells/mm3)±SD 9.9±6.6 8.6±5.3 6.6±4.1 <0.001ß 
median (cells/mm3) 8.7 8.1 5.9  
min-max 0.47-40 0.877-25.1 0.69-19.69  
n 372 51 74  
CRP       
mean (µg/L)±SD 53±71 37.4±86 108.8±94.2 NS 
median(µg/L) 24.7 15.6 12.7  
min-max 0.2-424.9 1.1-499.2 5-212.5  
n 107 34 5  
α- alveolar vs. non-alveolar CAP 
β- alveolar vs. clinical CAP 
γ- non-alveolar vs. clinical CAP 
NS- not significant 
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TABLE 3: Clinical and Laboratory Characteristics of Pediatric Patients 24-59 Months Old with CAP in 
Relation to Radiographic Categorizations. 
 
 Alveolar 
CAP 
Non-Alveolar 
CAP 
Clinical 
CAP 
P 
Fever >38.5°C % (n/N) 93.9 (372/396) 94.7 (36/38) 88.8 (79/89) NS 
Rhinorrea % (n/N) 58.8 (233/396) 63.2 (24/38) 38.6 (34/89) <0.001β, <0.019γ 
Cough% (n/N) 88.9 (352/396) 97.4 (37/38) 85.4 (76/89) NS 
<92 O2 sat% (n/N) 12 (47/396) 7.9 (3/38) 10.3 (9/89) NS 
Respiratory Rate ≥ 40 
breaths/min % (n/N) 45 (149/331) 62.2 (23/37) 62.7 (32/51) 0.07α, 0.027β 
Abdominal Pain% (n/N) 21.5 (85/396) 10.5 (4/38) 12.5 (11/88) 0.075β 
Vomiting% (n/N) 30.6 (121/396) 31.6 (12/38) 17 (15/88) 0.016β 
Vaccination Complete% 
(n/N) 
64.1 (207/323) 61.8 (21/34) 66.7 (22/33) NS 
Hospitalization% (n/N) 81.1 (321/396) 73.7 (28/38) 71.9 (64/89) 0.06β 
CRP >70µg/L% (n/N) 45.6 (67/147) 25 (5/20) 11.1 (1/9) 0.096α, 0.078β 
Respiratory Rate     
mean (breaths/min)±SD 38.7±11.47 40.92±10.38 41.59±11.52 NS 
median (breaths/min) 36 40 40  
min-max 18-80 24-64 20-68  
n 331 37 51  
Days of fever     
mean ± SD 3.7±3.8 2.5±2.4 2.3±2.2 <0.001α, β 
median 3 2 2  
min-max 0-30 0-12 0-10  
n 391 37 83  
WBC     
mean (cells/μl)± SD 18060±8752 14080±5170 12910±6346 <0.001α, β 
median 17000 14500 12320  
min-max 2460-51600 5700-25200 3760-38390  
n 351 29 60  
ANC     
mean (cells/mm3)±SD 13.4±8.1 10.2±4.7 8.2±5.3 <0.001α, β 
median (cells/mm3) 12.1 10.4 6.9  
min-max 1.1-42 2.3-21.5 1.0-25.6  
n 312 29 60  
CRP     
mean (µg/L)±SD 106.4±117.3 52.6±57.7 25.8±25.4 0.004β 
median(µg/L) 65 29.7 23.4  
min-max 0.2-771.1 3.6-196.8 1-86.1  
n 147 20 9  
α- alveolar vs. non-alveolar CAP 
β- alveolar vs. clinical CAP 
γ- non-alveolar vs. clinical CAP 
NS- not significant 
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TABLE 4: A Model Using Independent Parameters that Characterize Alveolar Community Acquired 
Pneumonia (CAP), Non-Alveolar CAP and Clinical CAP (No Chest X-Ray Defined Pneumonia). 
 
OR- odds ratio 
L- lower confidence limit 
U- upper confidence limit 
*- significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
Alveolar vs. Non-
alveolar CAP 
Alveolar vs. Clinical 
CAP 
Non-alveolar vs. 
Clinical CAP 
 CI (95%)  CI (95%)  CI (95%) 
OR L U OR L U OR L U 
ANC (cells/mm3) >15,000 1.73 0.94 3.66 2.02* 1.10 4.83 2.38 1.18 6.54 
Vaccine Status Fully 
Vaccinated 
0.43 0.21 1.02 0.61 0.27 1.44 0.60 0.25 1.48 
Age (years)   1.02* 1.01 1.04 1.00 0.99 1.02 1.00 0.993 1.02 
O2 Saturation ≤94% 0.54* 0.33 0.95 0.77 0.50 1.26 0.79 0.521 1.28 
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FIGURE LEGEND 
Figure 1: Distribution of radiographic presentations of children < 5 years of age with Community Acquired 
Pneumonia (CAP).   
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Figure 2: Characteristics of pediatric patients <5 years old with alveolar community acquired pneumonia 
(CAP), non-alveolar CAP and clinical CAP. Significant differences are denoted by α- alveolar vs. non-
alveolar CAP, β- alveolar vs. clinical CAP, and/or γ- non-alveolar vs. clinical CAP and are defined as P < 
0.05. 
 
 
 
